Topic: Nonpharmacologic Treatment of Mental Health Conditions in Pregnant and Postpartum People

Background

Perinatal mental health conditions include depression, anxiety, obsessive-compulsive disorder, bipolar disorder, and post-traumatic stress disorder. Data from the 2018 Pregnancy Risk Assessment Monitoring System showed the prevalence of postpartum depression was 13.2%, ranging from 9.7% in Illinois to 23.5% in Mississippi. Obsessive compulsive disorder affects 2 in 100 women in pregnancy and 2 -3 in every 100 women in the year after giving birth. About 18.0% of women in a population-based sample reported postpartum anxiety symptoms. The prevalence of PTSD in pregnancy ranges from 4-6%.

Mental health conditions in pregnancy appear to be increasing under the COVID pandemic. A cross-sectional survey of pregnant and postpartum women in 64 countries found that many women scored at or above the cut-offs for elevated posttraumatic stress (2,979 [43%]), anxiety/depression (2,138 [31%], and loneliness (3,691 [53%]). A majority of women (86%) reported being somewhat or very worried about COVID-19.⁵

Effects of untreated or undertreated perinatal mental health conditions can adversely impact not only the individual's own health but also infant outcomes, mother-infant bonding, and children's health. ⁶ AHRQ recently published a systematic review on pharmacologic treatment for mental health conditions in perinatal individuals which found few studies. ⁷ Thus, a review of perinatal non-pharmacologic treatments for mental health conditions is urgently needed, and can be used to inform clinical guidance.


Draft Key Questions

- 1. What is the effectiveness and comparative effectiveness and harms of non-pharmacologic treatments for mental health conditions in perinatal individuals?
 - a. Depressive disorders
 - b. Anxiety disorders
 - c. Post-traumatic stress disorder
 - d. Bipolar disorder
 - e. Obsessive-compulsive disorder
- 2. What is the effectiveness and harms of non-pharmacologic treatments compared with pharmacologic treatment alone for mental health conditions in perinatal individuals?
 - a. Depressive disorders
 - b. Anxiety disorders
 - c. Post-traumatic stress disorder
 - d. Bipolar disorder
 - e. Obsessive-compulsive disorder

PICO Table:

Element	KQ 1- Non-Pharm	KQ 2 Non-Pharm vs Pharm
Population	Perinatal individuals (pregnant,	Perinatal individuals (pregnant, lactating,
	lactating, postpartum up to one year	postpartum up to one year after delivery)
	after delivery)	on pharmacologic treatment for
	 a. Depressive disorders 	a. Depressive disorders
	b. Anxiety disorders	b. Anxiety disorders
	c. Post-traumatic stress disorder	c. Post-traumatic stress disorder
	d. Bipolar disorder	d. Bipolar disorder
	e. Obsessive-compulsive disorder	e. Obsessive-compulsive disorder
Intervention	Nonpharmacologic treatment	Nonpharmacologic treatment
		Co-intervention: pharmacologic treatment
Comparator	Placebo, no treatment,	Pharmacologic treatment
	Other non-pharmacological treatments	
Outcomes	Scores on psychological assessments,	Scores on psychological assessments,
	quality of life, adherence to treatment,	quality of life, adherence to treatment,
	maternal clinical outcomes,	maternal clinical outcomes,
	fetal/neonatal/pediatric clinical	fetal/neonatal/pediatric clinical outcomes
	outcomes	
		Harms of treatment
	Harms of treatment	

Draft Analytic Framework



References

- 1. Bauman BL, Ko JY, Cox S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression United States, 2018. MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):575-81. doi: 10.15585/mmwr.mm6919a2. PMID: 32407302. https://www.ncbi.nlm.nih.gov/pubmed/32407302
- **2.** Russell EJ, Fawcett JM, Mazmanian D. Risk of obsessive-compulsive disorder in pregnant and postpartum women: a meta-analysis. J Clin Psychiatry. 2013 Apr;74(4):377-85. doi: 10.4088/JCP.12r07917. PMID: 23656845. https://www.ncbi.nlm.nih.gov/pubmed/23656845
- **3.** Farr SL, Dietz PM, O'Hara MW, et al. Postpartum anxiety and comorbid depression in a population-based sample of women. J Womens Health (Larchmt). 2014 Feb;23(2):120-8. doi: 10.1089/jwh.2013.4438. PMID: 24160774. https://www.ncbi.nlm.nih.gov/pubmed/24160774
- **4.** Yildiz PD, Ayers S, Phillips L. The prevalence of posttraumatic stress disorder in pregnancy and after birth: A systematic review and meta-analysis. J Affect Disord. 2017 Jan 15;208:634-45. doi: 10.1016/j.jad.2016.10.009. PMID: 27865585
- **5.** Basu A, Kim HH, Basaldua R, et al. A cross-national study of factors associated with women's perinatal mental health and wellbeing during the COVID-19 pandemic. PLoS One. 2021;16(4):e0249780. doi: 10.1371/journal.pone.0249780. PMID: 33882096. https://www.ncbi.nlm.nih.gov/pubmed/33882096
- **6.** Stein A, Pearson RM, Goodman SH, et al. Effects of perinatal mental disorders on the fetus and child. Lancet. 2014 Nov 15;384(9956):1800-19. doi: 10.1016/s0140-6736(14)61277-0. PMID: 25455250
- 7. Viswanathan M, Middleton JC, Stuebe A, et al. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Systematic Review of Perinatal Pharmacologic Interventions. Rockville (MD); 2021.